917-13-5
Chemical Structure
Enniatin B
- CAS No.: 917-13-5
- Formula:C33H57N3O9
- Molecular Weight:639.82
IUPAC Name: (3S,6R,9S,12R,15S,18R)-3,6,9,12,15,18-hexaisopropyl-4,10,16-trimethyl-1,7,13-trioxa-4,10,16-triazacyclooctadecane-2,5,8,11,14,17-hexaone
InChIKey: MIZMDSVSLSIMSC-VYLWARHZSA-N
SMILES: CC([C@](O1)([H])C(N([C@H](C(O[C@@H](C(N([C@](C(C)C)([H])C(O[C@H](C(C)C)C(N(C)[C@@H](C(C)C)C1=O)=O)=O)C)=O)C(C)C)=O)C(C)C)C)=O)C
Biological Activity: Enniatin B is a Fusarium mycotoxin that acts as an ionophore to form cation-selective membrane channels, disrupt ion homeostasis and mitochondrial function, inhibit cell proliferation, and induce apoptosis, while modulating ERK, p38 MAPK, and STAT3 signaling pathways. Enniatin B is used in research on atherosclerosis, hypercholesterolemia, cervical cancer, and colon adenocarcinoma[1][2][3][4][5][6][7][8][9][10][11].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Enniatin B | Enniatin B is a Fusarium mycotoxin that acts as an ionophore to form cation-selective membrane channels, disrupt ion homeostasis and mitochondrial function, inhibit cell proliferation, and induce apoptosis, while modulating ERK, p38 MAPK, and STAT3 signaling pathways. Enniatin B is used in research on atherosclerosis, hypercholesterolemia, cervical cancer, and colon adenocarcinoma. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Enniatin B-13C33 | Enniatin B-13C33 is the 13C-labeled Enniatin B (HY-N3806). Enniatin B is a Fusarium mycotoxin that acts as an ionophore to form cation-selective membrane channels, disrupt ion homeostasis and mitochondrial function, inhibit cell proliferation, and induce apoptosis, while modulating ERK, p38 MAPK, and STAT3 signaling pathways. Enniatin B is used in research on atherosclerosis, hypercholesterolemia, cervical cancer, and colon adenocarcinoma. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Jonsson M, et al. Fusarium mycotoxin enniatin B: Cytotoxic effects and changes in gene expression profile. Toxicology in vitro : an international journal published in association with BIBRA. 2016 Aug;34:309-320.
- [2]. Prosperini A, et al. A Review of the Mycotoxin Enniatin B. Frontiers in public health. 2017;5:304.
- [3]. Kalayou S, et al. An investigation of the endocrine disrupting potential of enniatin B using in vitro bioassays. Toxicology letters. 2015 Mar 04;233(2):84-94. [Content Brief]
- [4]. Rodríguez-Carrasco Y, et al. Mouse tissue distribution and persistence of the food-born fusariotoxins Enniatin B and Beauvericin. Toxicology letters. 2016 Apr 15;247:35-44. [Content Brief]
- [5]. Ivanova L, et al. Lysosomes as a possible target of enniatin B-induced toxicity in Caco-2 cells. Chemical research in toxicology. 2012 Aug 20;25(8):1662-74. [Content Brief]
- [6]. Svingen T, et al. Enniatin B and beauvericin are common in Danish cereals and show high hepatotoxicity on a high-content imaging platform. Environmental toxicology. 2017 May;32(5):1658-1664.
- [7]. Ivanova L, et al. In vitro phase I metabolism of the depsipeptide enniatin B. Analytical and bioanalytical chemistry. 2011 Jul;400(9):2889-901.
- [8]. Behm C, et al. The Fusarium toxin enniatin B exerts no genotoxic activity, but pronounced cytotoxicity in vitro. Molecular nutrition & food research. 2009 Apr;53(4):423-30. [Content Brief]
- [9]. Ficheux AS, et al. Effects of beauvericin, enniatin b and moniliformin on human dendritic cells and macrophages: an in vitro study. Toxicon : official journal of the International Society on Toxinology. 2013 Sep;71:1-10. [Content Brief]
- [10]. Krug I, et al. Transport of enniatin B and enniatin B1 across the blood-brain barrier and hints for neurotoxic effects in cerebral cells. PloS one. 2018;13(5):e0197406. [Content Brief]
- [11]. Dornetshuber-Fleiss R, et al. The naturally born fusariotoxin enniatin B and sorafenib exert synergistic activity against cervical cancer in vitro and in vivo. Biochemical pharmacology. 2015 Feb 01;93(3):318-331. [Content Brief]
